17:47 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Antibe's pain candidate meets in Phase IIb GI safety trial

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) reported data from a double-blind, Canadian Phase IIb trial in 244 healthy volunteers undergoing gastroduodenal endoscopies showing that pain candidate ATB-346 for 14 days met the primary endpoint of improved...
21:28 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Antibe starts Phase II trial of ATB-346 in healthy volunteers

Antibe Therapeutics Inc. (TSX-V:ATE; OTCQX:ATBPF) began a Phase II trial of pain candidate ATB-346 in healthy volunteers. The double-blind, placebo-controlled trial will evaluate once-daily 250 mg ATB-346 for 14 days vs. naproxen sodium in 240...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ATB-346: Phase II data

An open-label, Canadian Phase II trial in 12 patients with OA of the knee showed that once-daily 250 mg oral ATB-346 reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score by 4.3 points...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

ATB-346: Phase II start

This month, Antibe will begin an open-label, Canadian Phase II trial to evaluate once-daily 250 mg oral ATB-346 in about 12-16 patients. Antibe Therapeutics Inc. (TSX-V:ATE), Hamilton, Ontario   Product: ATB-346   Business: Autoimmune  ...
08:00 , Nov 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclooxygenase-1 (COX-1); COX-2

Cancer INDICATION: Cancer Patient sample and mouse studies combining COX-1 and/or COX-2 inhibitors with immunotherapies could help treat cancer. In tumor samples from patients with cutaneous melanoma, levels of COX-2 mRNA correlated positively with levels...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

ATB-346: Phase I data

Data from Phase I trials showed that once-daily 250 mg oral ATB-346 for 14 days was well tolerated. Additionally, Antibe said once-daily 75-250 mg doses of ATB-346 inhibited COX for up to 24 hours after...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

ATB-346: Development resumed

Antibe resumed development of ATB-346 following collection and review of data from a double-blind, placebo-controlled, Canadian Phase I trial evaluating single and multiple ascending doses of oral ATB-346 in healthy volunteers. The company suspended the...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

ATB-346: Phase I halted

Antibe suspended a double-blind, placebo-controlled, Canadian Phase I trial evaluating single and multiple ascending doses of oral ATB-346 in healthy volunteers due to safety concerns. One subject had significant liver enzyme elevations in the highest...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

ATB-346: Phase I started

Antibe began a double-blind, placebo-controlled, Canadian Phase I trial to evaluate single and multiple ascending-doses of oral ATB-346 in healthy volunteers. Antibe Therapeutics Inc. (TSX-V:ATE), Hamilton, Ontario   Product: ATB-346   Business: Autoimmune   Molecular...
07:00 , Sep 16, 2013 |  BioCentury  |  Emerging Company Profile

Cardeus: Microglia blockade

Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc. 's COX-1 inhibitor tamps down neuroinflammation in the brain and could be synergistic with other treatments to keep dementia associated with diseases like Parkinson's in check. Activation of...